APP
FATE icon

Alpha Paradigm Partners’s Fate Therapeutics FATE Stock Holding History

Alpha Paradigm Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-56,644
Closed -$1.27M – 517
2022
Q3 		$1.27M Buy
56,644
+12,491
+28% +$361K 0.55% 42
2022
Q2 		$1.09M Buy
+44,153
New +$1.22M 0.45% 57

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpha Paradigm Partners's FATE Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 56,644 shares — an estimated $1.27M sold.

Alpha Paradigm Partners first reported a position in FATE in Q2 2022 and held it in 2 quarters. The position peaked at $1.27M in Q3 2022. 228 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Alpha Paradigm Partners reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 56,644 Fate Therapeutics shares in Q4 2022, an estimated $1.27M.
  • Alpha Paradigm Partners first reported a position in Fate Therapeutics in Q2 2022 and held it in 2 quarters.
  • Alpha Paradigm Partners's Fate Therapeutics position peaked at $1.27M in Q3 2022.
  • 228 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.